赛诺菲：更强的产品上市与新的研发重置，让重估理由继续存在（纳斯达克：SNY）
· seekingalpha.com
赛诺菲第二季度上调指引，Dupixent推动2026年展望；更快的产品上市实现了收入多元化。
In our last update, we provided a deep dive into Sanofi ( SNY ) ( SNYNF ) patent cliff and exposure to its major drug (Dupixent). We maintained our Buy rating d...